Merck Looks Beyond First-In-Class Only As It Seeks To Bolster R&D Productivity
Executive Summary
With three large outcomes studies to read out interim or final results, 2012 is likely to be a pivotal year for Merck’s R&D, even as it rebalances its traditionally first-in-class emphasis to a hybrid model that also embraces best in class.
You may also be interested in...
MSD India Managing Director K.G. Ananthakrishnan On Disease Management And Taking A Holistic Approach: An Interview With PharmAsia News (Part 2 of 2)
Merck Sharp & Dohme India Managing Director K.G. Ananthakrishnan discusses MSD’s holistic approach to patient care in India, including disease management, physician education and responsible pricing.
Merck Launches FosaMax Plus In China; More Launches For Diabetes And Cardiovascular Drugs Expected
Following Eli Lilly’s launch of Forteo in China last November, Merck is launching FosaMax Plus, a vitamin D compounded version of its osteoporosis blockbuster FosaMax.
Diabetes Franchise May Help Merck Offset Loss Of Singulair
The Januvia/Janumet franchise posted sales growth of 40% both in the fourth quarter and over the full year for Merck, while Isentress and Gardasil also posted strong growth rates.